A Case of Switching from GnRH Agonist to Antagonist for Castration Resistant Prostate Cancer Control.
CRPC
Degarelix
GnRH antagonist
Journal
Case reports in oncology
ISSN: 1662-6575
Titre abrégé: Case Rep Oncol
Pays: Switzerland
ID NLM: 101517601
Informations de publication
Date de publication:
Historique:
received:
14
08
2019
accepted:
21
08
2019
entrez:
15
10
2019
pubmed:
15
10
2019
medline:
15
10
2019
Statut:
epublish
Résumé
GnRH antagonist and GnRH agonist are widely used as androgen deprivation therapy for metastatic prostate cancer. A previous report demonstrated that patients with PSA levels of >20 ng/mL using GnRH antagonists showed favorable outcomes in comparison to those using GnRH agonists. An 82-year old male patient with edema, a stony hard nodule on his prostate, and an initial PSA level of 6,717 ng/mL was referred to our hospital due to suspected prostate cancer. He received prostate needle biopsy and was diagnosed with prostate cancer with bone metastasis, with a Gleason Score of 4 + 4 = 8. He was then treated with a GnRH agonist (leuprorelin acetate) and bicalutamide from July 2015. Although his PSA level decreased to 582.0 ng/mL in December 2015, his PSA level gradually increased and CRPC developed. He indicated that he did not wish to take 2nd generation anti-androgen drugs or receive systemic chemotherapy. We introduced a GnRH antagonist (degarelix) in February 2015; his PSA level did not change and his CRPC was controlled. We herein report a case in which changing a GnRH agonist to a GnRH antagonist contributed to CRPC control.
Identifiants
pubmed: 31607884
doi: 10.1159/000502859
pii: cro-0012-0688
pmc: PMC6787414
doi:
Types de publication
Case Reports
Langues
eng
Pagination
688-692Informations de copyright
Copyright © 2019 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest in association with the present study.
Références
Expert Opin Pharmacother. 2017 Jun;18(8):825-832
pubmed: 28480768
N Engl J Med. 2014 Jul 31;371(5):424-33
pubmed: 24881730
Oncol Ther. 2017;5(1):119-123
pubmed: 28680962
Eur Urol. 2014 Feb;65(2):467-79
pubmed: 24321502
BJU Int. 2017 Dec;120(6):751-754
pubmed: 28834013
Eur Urol. 2014 Dec;66(6):1101-8
pubmed: 24440304
Ther Adv Urol. 2015 Jun;7(3):105-15
pubmed: 26161141
N Engl J Med. 2012 Sep 27;367(13):1187-97
pubmed: 22894553
Ann Surg. 1942 Jun;115(6):1192-200
pubmed: 17858048
Med J Islam Repub Iran. 2016 Jan 09;30:317
pubmed: 27390687
BMC Res Notes. 2015 Aug 05;8:335
pubmed: 26242866